AZD7325 - CAS:942437-37-8

您当前的位置：

AZD7325

目录号 : KM5948 CAS No. : 942437-37-8 纯度 : 98%

Data Sheet 产品使用指南

AZD7325 是具有口服活性的 α2,3 receptor 的正向别构调节剂 (PAM)，K_i 分别是 0.3 and 1.3 nM，但在 α1 和 α5 受体亚型上效果较差。AZD7325 是一种中等 CYP1A2 和强效 CYP3A4 诱导剂。AZD7325 具有用于焦虑和 dravet 综合征相关研究的潜力。

规格	价格	是否有货
5mg		In-stock
10mg		In-stock
50mg		In-stock
100mg		In-stock
200mg	询价	In-stock
500mg	询价	In-stock

查看所有商品（1）

加入购物车大包装询价

Other Forms of Rapamycin:

Ginkgolide J In-stock
Ginkgolide K In-stock
THK-5470 In-stock
NH-3 In-stock
Velufenacin In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

AZD7325 is a potent and orally active partial selective PAM of GABAAα2 and Aα3 receptor (K_i=0.3 and 1.3 nM, respectively), and has less antagonistic efficacy at the Aα1 and Aα5 receptor subtypes. AZD7325 is a moderate CYP1A2 and a potent CYP3A4 inducer in vitro. AZD7325 has the potential for the investigation of anxiety and dravet syndrome. PAM: positive allosteric modulator.

体外研究

AZD7325 is a high affinity and selective modulator of the GABAA receptor system, exhibits high binding affinity at GABAAα1, α2 and α3 (K_i=0.5, 0.3, and 1.3 nM, respectively), and low at GABAAα5 (K_i=230 nM).
AZD7325 (0-10 µM; 3 consecutive days; once daily) causes a maximal CYP1A2 mRNA expression of 3.2-fold, 2.1-fold, and 2.5-fold in human hepatocytes from donor HH210, HH215, and HH216, respectively.
AZD7325 (0-10 µM; 3 consecutive days; once daily) causes CYP1A2 and CYP3A4 protein expression in human hepatocytes from donor HH210.

RT-PCR

Cell Line:	Primary human hepatocytes from one female (HH210) and two male (HH215, HH216) donors
Concentration:	0.01, 0.1, 1, 10 µM
Incubation Time:	3 consecutive days
Result:	Led to increase of CYP1A2 mRNA expression

Western Blot Analysis

Cell Line:	Primary human hepatocytes from donors
Concentration:	0.01, 0.1, 1, 10 µM
Incubation Time:	3 consecutive days
Result:	Increased CYP1A2 and CYP3A4 protein level.

体内研究

AZD7325 (oral administration; 10, 17.8 or 31.6 mg/kg; 30 minutes before the induction of hyperthermia) attenuates hyperthermia-induced seizures, shows median thresholds in the treatment groups of 42.8°C for 10 mg/kg, 43.3°C for 17.8 mg/kg, and 43.4°C for 31.6 mg/kg compares to 42.2°C in vehicle group.

Animal Model:	Male and female P18 - P20 F1.Scn1a mice
Dosage:	10, 17.8 or 31.6 mg/kg
Administration:	Oral administration; 30 minutes before the induction of hyperthermia
Result:	Attenuated hyperthermia-induced seizures in F1.Scn1a mice with no sedative effect.

分子式

C₁₉H₁₉FN₄O₂

分子量

354.38

CAS号

942437-37-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 250 mg/mL (705.46 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.8218 mL	14.1091 mL	28.2183 mL
5 mM	0.5644 mL	2.8218 mL	5.6437 mL
10 mM	0.2822 mL	1.4109 mL	2.8218 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (5.87 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.87 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.87 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.87 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

临床试验

纯度： 98%

Data Sheet

产品使用指南

摩尔计算器
稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量

浓度

体积

分子量*

重置计算

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度

体积

浓度

体积

重置计算

Other Forms of Rapamycin:

KKL 顾客使用本产品发表的 0 篇科研文献

The molarity calculator equation

The dilution calculator equation